AIMA
NVO

Ables Iannone Moore & Associates’s Novo Nordisk NVO Stock Holding History

Ables Iannone Moore & Associates’s Portfolio NVO Stock Details NVO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-14
Closed -$1.45K – 215
2023
Q4 		$1.45K Buy
+14
New +$1.38K ﹤0.01% 241

Other funds holding NVO

Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Fayez Sarofim & Co
Fayez Sarofim & Co Houston, Texas $39.1B AUM 15.14% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return
F
Folketrygdfondet Oslo Norway, Norway $5.64B AUM 47.16% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Ables Iannone Moore & Associates's NVO Position: Q1 2024 in Review

Ables Iannone Moore & Associates sold out of Novo Nordisk (NVO) in Q1 2024, closing a stake of 14 shares — an estimated $1.45K sold.

Ables Iannone Moore & Associates first reported a position in NVO in Q4 2023 and held it in 1 quarter. The position peaked at $1.45K in Q4 2023. 1,744 funds tracked by Wall St. Rank hold NVO as of Q1 2024.

  • Ables Iannone Moore & Associates reported no remaining Novo Nordisk position as of Q1 2024 after selling out during the quarter.
  • Ables Iannone Moore & Associates sold 14 Novo Nordisk shares in Q1 2024, an estimated $1.45K.
  • Ables Iannone Moore & Associates first reported a position in Novo Nordisk in Q4 2023 and held it in 1 quarter.
  • Ables Iannone Moore & Associates's Novo Nordisk position peaked at $1.45K in Q4 2023.
  • 1,744 funds tracked by Wall St. Rank held Novo Nordisk as of Q1 2024.

Based on Ables Iannone Moore & Associates's 13F filing for Q1 2024, filed 30 Apr 2024.